☰

Bissan Al-Lazikani - Publications

Affiliations: 
Cancer Therapeutics Unit The Institute of Cancer Research 
Tree Info Similar researchers PubMed Report error

44 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Neeb A, Figueiredo I, Bogdan D, Cato L, Stober J, Jiménez-Vacas JM, Gourain V, Lee II, Seeger R, Muhle-Goll C, Gurel B, Welti J, Nava Rodrigues D, Rekowski J, Qiu X, ... ... Al-Lazikani B, et al. Thio-2 inhibits key signaling pathways required for the development and progression of castration resistant prostate cancer. Molecular Cancer Therapeutics. PMID 38412481 DOI: 10.1158/1535-7163.MCT-23-0354  0.313
2023 di Micco P, Antolin AA, Mitsopoulos C, Villasclaras-Fernandez E, Sanfelice D, Dolciami D, Ramagiri P, Mica IL, Tym JE, Gingrich PW, Hu H, Workman P, Al-Lazikani B. canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research. 51: D1212-D1219. PMID 36624665 DOI: 10.1093/nar/gkac1004  0.814
2022 Antolin AA, Sanfelice D, Crisp A, Villasclaras Fernandez E, Mica IL, Chen Y, Collins I, Edwards A, Müller S, Al-Lazikani B, Workman P. The Chemical Probes Portal: an expert review-based public resource to empower chemical probe assessment, selection and use. Nucleic Acids Research. PMID 36268860 DOI: 10.1093/nar/gkac909  0.759
2022 Dolciami D, Villasclaras-Fernandez E, Kannas C, Meniconi M, Al-Lazikani B, Antolin AA. canSAR chemistry registration and standardization pipeline. Journal of Cheminformatics. 14: 28. PMID 35643512 DOI: 10.1186/s13321-022-00606-7  0.714
2022 Coker EA, Stewart A, Ozer B, Minchom AR, Pickard L, Ruddle R, Carreira S, Popat S, O'Brien ME, Raynaud FI, de Bono JS, Al-Lazikani B, Banerji U. Individualised prediction of drug response and rational combination therapy in NSCLC using artificial intelligence enabled studies of acute phosphoproteomic changes. Molecular Cancer Therapeutics. PMID 35368084 DOI: 10.1158/1535-7163.MCT-21-0442  0.777
2021 Müller S, Ackloo S, Al Chawaf A, Al-Lazikani B, Antolin A, Baell JB, Beck H, Beedie S, Betz UAK, Bezerra GA, Brennan PE, Brown D, Brown PJ, Bullock AN, Carter AJ, et al. Target 2035 - update on the quest for a probe for every protein. Rsc Medicinal Chemistry. 13: 13-21. PMID 35211674 DOI: 10.1039/d1md00228g  0.749
2021 Antolin AA, Clarke PA, Collins I, Workman P, Al-Lazikani B. Evolution of kinase polypharmacology across HSP90 drug discovery. Cell Chemical Biology. PMID 34077750 DOI: 10.1016/j.chembiol.2021.05.004  0.78
2020 Mitsopoulos C, Di Micco P, Fernandez EV, Dolciami D, Holt E, Mica IL, Coker EA, Tym JE, Campbell J, Che KH, Ozer B, Kannas C, Antolin AA, Workman P, Al-Lazikani B. canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research. PMID 33219674 DOI: 10.1093/nar/gkaa1059  0.821
2020 Darby JF, Vidler LR, Simpson PJ, Al-Lazikani B, Matthews SJ, Sharp SY, Pearl LH, Hoelder S, Workman P. Solution structure of the Hop TPR2A domain and investigation of target druggability by NMR, biochemical and in silico approaches. Scientific Reports. 10: 16000. PMID 32994435 DOI: 10.1038/s41598-020-71969-w  0.519
2020 Zhang C, Stockwell SR, Elbanna M, Ketteler R, Freeman J, Al-Lazikani B, Eccles S, De Haven Brandon A, Raynaud F, Hayes A, Clarke PA, Workman P, Mittnacht S. Correction: Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases. Oncogene. PMID 32094403 DOI: 10.1038/s41388-020-1221-8  0.416
2020 Antolin AA, Ameratunga M, Banerji U, Clarke PA, Workman P, Al-Lazikani B. The kinase polypharmacology landscape of clinical PARP inhibitors. Scientific Reports. 10: 2585. PMID 32066817 DOI: 10.1038/s41598-020-59074-4  0.753
2019 Antolin AA, Workman P, Al-Lazikani B. Public resources for chemical probes: the journey so far and the road ahead. Future Medicinal Chemistry. 13: 731-747. PMID 31778323 DOI: 10.4155/fmc-2019-0231  0.741
2019 Zhang C, Stockwell SR, Elbanna M, Ketteler R, Freeman J, Al-Lazikani B, Eccles S, De Haven Brandon A, Raynaud F, Hayes A, Clarke PA, Workman P, Mittnacht S. Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases. Oncogene. PMID 31296956 DOI: 10.1038/s41388-019-0850-2  0.478
2019 Workman P, Antolin AA, Al-Lazikani B. Transforming cancer drug discovery with Big Data and AI. Expert Opinion On Drug Discovery. 14: 1089-1095. PMID 31284790 DOI: 10.1080/17460441.2019.1637414  0.787
2019 Stewart A, Coker EA, Pölsterl S, Georgiou A, Minchom AR, Carreira S, Cunningham D, O'Brien MER, Raynaud FI, de Bono JS, Al-Lazikani B, Banerji U. Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in -Mutant Cancers. Molecular Cancer Therapeutics. PMID 31262731 DOI: 10.1158/1535-7163.MCT-18-0727  0.754
2019 Coker EA, Mitsopoulos C, Tym JE, Komianou A, Kannas C, Di Micco P, Villasclaras Fernandez E, Ozer B, Antolin AA, Workman P, Al-Lazikani B. canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research. 47: D917-D922. PMID 30496479 DOI: 10.1093/nar/gky1129  0.819
2018 Kinnersley B, Sud A, Coker EA, Tym JE, Di Micco P, Al-Lazikani B, Houlston RS. Leveraging Human Genetics to Guide Cancer Drug Development. Jco Clinical Cancer Informatics. 2: 1-11. PMID 30652614 DOI: 10.1200/CCI.18.00077  0.787
2018 Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, Zamora J, Butler A, Whitaker H, Kote-Jarai Z, Alexandrov LB, Van Loo P, Massie CE, Dentro S, Warren AY, ... ... Al-Lazikani B, et al. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature Genetics. PMID 29662167 DOI: 10.1038/S41588-018-0086-Z  0.575
2018 Antolin AA, Workman P, Mestres J, Al-Lazikani B. Polypharmacology in Precision Oncology: Current Applications and Future Prospects. Current Pharmaceutical Design. 22: 6935-6945. PMID 27669965 DOI: 10.2174/1381612822666160923115828  0.827
2017 Antolin AA, Tym JE, Komianou A, Collins I, Workman P, Al-Lazikani B. Objective, Quantitative, Data-Driven Assessment of Chemical Probes. Cell Chemical Biology. PMID 29249694 DOI: 10.1016/J.Chembiol.2017.11.004  0.721
2017 Coker EA, Mitsopoulos C, Workman P, Al-Lazikani B. SiGNet: A signaling network data simulator to enable signaling network inference. Plos One. 12: e0177701. PMID 28545060 DOI: 10.1371/journal.pone.0177701  0.737
2016 Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG, Karlsson A, Al-Lazikani B, Hersey A, Oprea TI, Overington JP. A comprehensive map of molecular drug targets. Nature Reviews. Drug Discovery. PMID 27910877 DOI: 10.1038/nrd.2016.230  0.466
2016 Al-Lazikani B, Workman P. Minimizing bias in target selection by exploiting multidisciplinary Big Data and the protein interactome. Future Medicinal Chemistry. 8: 1711-6. PMID 27580970 DOI: 10.4155/fmc-2016-0133  0.516
2016 Yap TA, Smith AD, Ferraldeschi R, Al-Lazikani B, Workman P, de Bono JS. Drug discovery in advanced prostate cancer: translating biology into therapy. Nature Reviews. Drug Discovery. PMID 27444228 DOI: 10.1038/nrd.2016.120  0.597
2016 Campbell J, Ryan CJ, Brough R, Bajrami I, Pemberton HN, Chong IY, Costa-Cabral S, Frankum J, Gulati A, Holme H, Miller R, Postel-Vinay S, Rafiq R, Wei W, Williamson CT, ... ... Al-Lazikani B, et al. Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. Cell Reports. PMID 26947069 DOI: 10.1016/j.celrep.2016.02.023  0.38
2016 Workman P, Clarke PA, Al-Lazikani B. Blocking the survival of the nastiest by HSP90 inhibition. Oncotarget. 7: 3658-61. PMID 26820296 DOI: 10.18632/oncotarget.6971  0.574
2016 Tym JE, Mitsopoulos C, Coker EA, Razaz P, Schierz AC, Antolin AA, Al-Lazikani B. canSAR: an updated cancer research and drug discovery knowledgebase. Nucleic Acids Research. 44: D938-43. PMID 26673713 DOI: 10.1093/nar/gkv1030  0.835
2015 Mitsopoulos C, Schierz AC, Workman P, Al-Lazikani B. Distinctive Behaviors of Druggable Proteins in Cellular Networks. Plos Computational Biology. 11: e1004597. PMID 26699810 DOI: 10.1371/journal.pcbi.1004597  0.65
2015 Pearl LH, Schierz AC, Ward SE, Al-Lazikani B, Pearl FM. Therapeutic opportunities within the DNA damage response. Nature Reviews. Cancer. 15: 166-80. PMID 25709118 DOI: 10.1038/nrc3891  0.437
2014 Bulusu KC, Tym JE, Coker EA, Schierz AC, Al-Lazikani B. canSAR: updated cancer research and drug discovery knowledgebase. Nucleic Acids Research. 42: D1040-7. PMID 24304894 DOI: 10.1093/nar/gkt1182  0.813
2014 Workman P, Al-Lazikani B. Drugging cancer genomes. Nature Reviews. Drug Discovery. 12: 889-90. PMID 24287764 DOI: 10.1038/nrd4184  0.619
2013 Workman P, Al-Lazikani B, Clarke PA. Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. Current Opinion in Pharmacology. 13: 486-96. PMID 23810823 DOI: 10.1016/j.coph.2013.06.004  0.642
2013 Al-Lazikani B, Workman P. Unpicking the combination lock for mutant BRAF and RAS melanomas. Cancer Discovery. 3: 14-9. PMID 23319765 DOI: 10.1158/2159-8290.CD-12-0520  0.518
2013 Patel MN, Halling-Brown MD, Tym JE, Workman P, Al-Lazikani B. Objective assessment of cancer genes for drug discovery. Nature Reviews. Drug Discovery. 12: 35-50. PMID 23274470 DOI: 10.1038/nrd3913  0.645
2012 Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nature Biotechnology. 30: 679-92. PMID 22781697 DOI: 10.1038/nbt.2284  0.64
2012 Workman P, Clarke PA, Al-Lazikani B. Personalized medicine: patient-predictive panel power. Cancer Cell. 21: 455-8. PMID 22516256 DOI: 10.1016/j.ccr.2012.03.030  0.394
2012 Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Research. 40: D1100-7. PMID 21948594 DOI: 10.1093/Nar/Gkr777  0.427
2011 Halling-Brown MD, Bulusu KC, Patel M, Tym JE, Al-Lazikani B. canSAR: an integrated cancer public translational research and drug discovery resource. Nucleic Acids Research. 40: D947-56. PMID 22013161 DOI: 10.1093/nar/gkr881  0.816
2011 Bellis LJ, Akhtar R, Al-Lazikani B, Atkinson F, Bento AP, Chambers J, Davies M, Gaulton A, Hersey A, Ikeda K, Krüger FA, Light Y, McGlinchey S, Santos R, Stauch B, et al. Collation and data-mining of literature bioactivity data for drug discovery. Biochemical Society Transactions. 39: 1365-70. PMID 21936816 DOI: 10.1042/Bst0391365  0.473
2011 Orchard S, Al-Lazikani B, Bryant S, Clark D, Calder E, Dix I, Engkvist O, Forster M, Gaulton A, Gilson M, Glen R, Grigorov M, Hammond-Kosack K, Harland L, Hopkins A, et al. Minimum information about a bioactive entity (MIABE). Nature Reviews. Drug Discovery. 10: 661-9. PMID 21878981 DOI: 10.1038/Nrd3503  0.356
2011 Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, Schraml P, Moch H, Cassidy AM, Brewer D, Al-Lazikani B, Workman P, De-Bono J, Kaye SB, Larkin J, et al. A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Science Translational Medicine. 3: 85ra47. PMID 21632985 DOI: 10.1126/scitranslmed.3002004  0.48
2009 Berriman M, Haas BJ, LoVerde PT, Wilson RA, Dillon GP, Cerqueira GC, Mashiyama ST, Al-Lazikani B, Andrade LF, Ashton PD, Aslett MA, Bartholomeu DC, Blandin G, Caffrey CR, Coghlan A, et al. The genome of the blood fluke Schistosoma mansoni. Nature. 460: 352-8. PMID 19606141 DOI: 10.1038/Nature08160  0.313
2008 Agüero F, Al-Lazikani B, Aslett M, Berriman M, Buckner FS, Campbell RK, Carmona S, Carruthers IM, Chan AW, Chen F, Crowther GJ, Doyle MA, Hertz-Fowler C, Hopkins AL, McAllister G, et al. Genomic-scale prioritization of drug targets: the TDR Targets database. Nature Reviews. Drug Discovery. 7: 900-7. PMID 18927591 DOI: 10.1038/Nrd2684  0.421
2006 Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nature Reviews. Drug Discovery. 5: 993-6. PMID 17139284 DOI: 10.1038/nrd2199  0.434
Show low-probability matches.